American Academy of Neurology (AAN) 2026 Annual Meeting

The 48-month analysis of the global phase III Clarity AD study shows that lecanemab continues to deliver benefit and delay progression in early Alzheimer's disease (AD).

An open-label extension (OLE) study demonstrates the long-term safety, tolerability, and efficacy of atogepant for migraine prevention.

Treatment with semaglutide appears effective in reducing the risk of adult-onset epilepsy or seizures relative to sodium–glucose cotransporter-2 inhibitors (SGLT2i) and other glucose-lowering drugs (GLDs) in patients with type 2 diabetes mellitus (T2DM), according to a study presented at AAN 2026.

The use of fremanezumab in children and adolescents with episodic migraine (EM) results in significant reductions in monthly migraine days (MMD) and monthly headache days (MHD), but it appears to be no better than placebo among those with chronic migraine (CM), as shown by outcomes from two randomized, phase III trials presented at AAN 2026.